抗纤维化乳房假体表面涂层显著减少假体周围包膜形成
研究在小鼠模型中比较了未涂层与Met-Z2-Y12抗炎涂层硅胶假体周围的包膜厚度,在21、90、180天三个时间点,涂层假体的包膜厚度均较未涂层假体出现统计学显著降低(P < 0.05),提示该表面化学修饰可能减轻包膜挛缩。
要点
- Met-Z2-Y12涂层硅胶假体在21、90、180天包膜厚度均较未涂层假体统计学显著降低(P < 0.05)。
- 包膜形成先于包膜挛缩,结果提示挛缩本身可能被显著减弱。
- 该化学修饰可能超越乳房假体,应用于其他可植入医疗器械。
核心结论
- 在小鼠乳房增大与重建的假体植入模型中,硅胶假体表面Met-Z2-Y12涂层显著减少急性和慢性包膜形成。
- 由于包膜形成必然先于包膜挛缩,这些结果提示挛缩本身可能被显著减弱。
- 假体周围包膜形成是无解剖边界的并发症,该化学修饰可能超越乳房假体应用于多种其他可植入医疗器械。
研究设计与样本
- 研究将硅胶假体涂覆Met-Z2-Y12(一种生物相容性抗炎表面修饰),并将未涂层与Met-Z2-Y12涂层假体植入C57BL/6小鼠。
- 于21、90或180天后取出假体周围组织进行组织学分析。
主要发现
- 作者比较了三个时间点的平均包膜厚度。
- 在21、90和180天,Met-Z2-Y12涂层假体较未涂层假体的包膜厚度出现统计学显著降低(P < 0.05)。
关键数值与推荐
- 在21、90和180天,Met-Z2-Y12涂层假体较未涂层假体的包膜厚度降低,P < 0.05。
临床怎么用
- 在小鼠模型中,硅胶假体表面Met-Z2-Y12涂层改变假体周围包膜结构,并在术后至少6个月内显著减少包膜厚度。
- 作者认为这是开发预防包膜挛缩疗法中有希望的一步。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The body responds to prosthetic materials with an inflammatory foreign body response and deposition of a fibrous capsule, which may be deleterious to the function of the device and cause significant discomfort for the patient. Capsular contracture (CC) is the most common complication of aesthetic and reconstructive breast surgery. The source of significant patient morbidity, it can result in pain, suboptimal aesthetic outcomes, implant failure, and increased costs. The underlying mechanism remains unknown. Treatment is limited to reoperation and capsule excision, but recurrence rates remain high. In this study, the authors altered the surface chemistry of silicone implants with a proprietary anti-inflammatory coating to reduce capsule formation. METHODS: Silicone implants were coated with Met-Z2-Y12, a biocompatible, anti-inflammatory surface modification. Uncoated and Met-Z2-Y12-coated implants were implanted in C57BL/6 mice. After 21, 90, or 180 days, periprosthetic tissue was removed for histologic analysis. RESULTS: The authors compared mean capsule thickness at three time points. At 21, 90, and 180 days, there was a statistically significant reduction in capsule thickness of Met-Z2-Y12-coated implants compared with uncoated implants ( P < 0.05). CONCLUSIONS: Coating the surface of silicone implants with Met-Z2-Y12 significantly reduced acute and chronic capsule formation in a mouse model for implant-based breast augmentation and reconstruction. As capsule formation obligatorily precedes CC, these results suggest contracture itself may be significantly attenuated. Furthermore, as periprosthetic capsule formation is a complication without anatomical boundaries, this chemistry may have additional applications beyond breast implants, to a myriad of other implantable medical devices. CLINICAL RELEVANCE STATEMENT: Coating of the silicone implant surface with Met-Z2-Y12 alters the periprosthetic capsule architecture and significantly reduces capsule thickness for at least 6 months postoperatively in a murine model. This is a promising step forward in the development of a therapy to prevent capsular contracture.
引用
- Karinja SJ, Bernstein JL, Mukherjee S, et al. An Antifibrotic Breast Implant Surface Coating Significantly Reduces Periprosthetic Capsule Formation. Plast Reconstr Surg. 2023. PMID: 36847657. doi:10.1097/PRS.0000000000010323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。